Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L8OP
|
|||
| Former ID |
DIB015081
|
|||
| Drug Name |
AVP-21D9
|
|||
| Synonyms |
Thravixa; AVP-1C6; AVP-22G12; AVP-8C1; Anthrax antibody, AVANIR; Anthrax toxin Mab, Xenerex; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), AVANIR; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), Emergent
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Bacillus anthracis infection [ICD-11: 1G40] | Phase 1 | [1] | |
| Company |
Emergent biosolutions
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Protective antigen (Bact pagA) | Target Info | . | [2] |
| Pathway Interaction Database | Cellular roles of Anthrax toxin | |||
| Reactome | Uptake and function of anthrax toxins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01202695) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9). U.S. National Institutes of Health. | |||
| REF 2 | Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.